Asian Journal of Pharmaceutical Education and Research
Vol -14, Issue-3, July- September 2025
ISSN:2278 7496

REVIEW ARTICLE Impact Factor: 7.014

SOLID DISPERSIONS: A COMPREHENSIVE TOOL FOR OVERCOMING POOR DRUG SOLUBILITY

Swaraj Boddu, Harshit Kumar, Balwant Singh Rawat*, Vipin Kumar
Department of Pharmaceutical Sciences, GurukulaKangri (Deemed to be University), Haridwar, Uttarakhand. 249404

*Corresponding Author's E mail: bsrawat1981@gmail.com

Received 21 June 2025; Revised 23 June. 2025; Accepted 30 June. 2025, Available online 15 July. 2025

Cite this article as: Boddu S, Rawat BS and Kumar V. Solid Dispersions: A Comprehensive Tool for Overcoming Poor Drug Solubility. Asian Journal of Pharmaceutical Education and Research. 2025; 14(3): 29-42.

https://dx.doi.org/10.38164/AJPER/14.3.2025.43-61

ABSTRACT

Improving the oral bioavailability of drugs administered in solid dosage forms remains a significant challenge for formulation scientists, primarily due to poor aqueous solubility. For drugs with low solubility, the rate at which they dissolve can often be the limiting step in their absorption within the gastrointestinal tract. Consequently, enhancing the dissolution rate of these compounds is crucial to improving their therapeutic effectiveness. One promising approach is the use of solid dispersion techniques, which have gained widespread attention for their ability to increase the dissolution rate of poorly water-soluble, lipophilic drugs. This method enhances bioavailability by decreasing particle size, increasing wettability, and converting the drug into an amorphous form, which generally dissolves more readily than its crystalline counterpart. Solid dispersions typically consist of at least two components: a hydrophobic drug and a hydrophilic inert carrier or matrix. The technique involves dispersing the drug in the carrier to form a solid product that improves drug release characteristics. This review explores the development of solid dispersion technology, including its classification, methods of preparation, and their respective advantages and limitations. In addition, it highlights recent progress in the field and provides insights into the selection of appropriate carriers and preparation techniques based on available data and practical considerations.

Keywords: Poorly soluble drugs; solid dispersion; solubility enhancement; bioavailability improvement.

INTRODUCTION

The oral route remains the most preferred and convenient method for drug administration, owing to advantages such as improved patient compliance, ease of administration, accurate dosing, cost-effective manufacturing, and enhanced stability of formulations[1,2]. However, the formulation of drugs with poor aqueous solubility continues to be a major challenge in pharmaceutical development.

A significant proportion approximately 40% of new chemical entities identified by the pharmaceutical industry, exhibit low water solubility, which adversely affects their dissolution rate and oral

bioavailability. As a result, such compounds often require higher doses to achieve therapeutic levels, potentially increasing the risk of adverse effects and systemic toxicity. To overcome these limitations, enhancing the solubility of poorly water-soluble drugs has become a critical focus in formulation science. Improving solubility not only increases dissolution rate but also leads to improved absorption and bioavailability.

Solid dispersion

Among the various formulation strategies available to enhance the solubility of poorly water-soluble drugs, solid dispersion stands out as one of the most effective and widely studied approaches. Solid dispersion refers to a system comprising at least two distinct components: a hydrophobic drug and a hydrophilic carrier or matrix. These carriers can exist in either a crystalline or amorphous state. Amorphous matrices are generally preferred due to their higher solubility and dissolution rate, which result from the absence of a crystal lattice structure those otherwise needs to be broken during the dissolution process. The improved wettability and solubilization of the drug are typically attributed to the surrounding hydrophilic matrix[3,4].

First-generation solid dispersions

The concept of solid dispersion was initially introduced by Sekiguchi and Obi in 1961, who proposed the use of eutectic mixtures to enhance the dissolution of poorly soluble drugs. These systems typically employed crystalline carriers such as urea or mannitol. In eutectic mixtures, the drug and carrier form a binary system that co-crystallizes at a specific composition, known as the eutectic point. Upon contact with an aqueous medium, the hydrophilic carrier dissolves rapidly, releasing the drug in the form of fine crystalline particles, which enhances its dissolution rate[3,5]. However, a key limitation of first-generation systems lies in their crystalline nature, which offers inferior solubility compared to amorphous forms. Despite this, they maintain good thermodynamic stability. First-generation solid dispersions served as a foundational approach and paved the way for further advancements in the field.

Second-generation solid dispersions

The second generation of solid dispersions replaced crystalline carriers with amorphous polymeric matrices, which are capable of enhancing solubility to a greater extent due to their disordered structure. These carriers include synthetic polymers such as polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), and polymethacrylates, as well as naturally derived polymers like hydroxypropyl

methylcellulose (HPMC), ethyl cellulose, and cyclodextrin derivatives. Based on the molecular interaction between the drug and carrier, these systems can be further categorized into solid solutions, solid suspensions, or a combination of both. The amorphous nature of the carrier allows the drug to remain in a high-energy, non-crystalline state, which significantly enhances dissolution and absorption.

Third-generation solid dispersions

Third-generation solid dispersions utilize surfactants or self-emulsifying carriers, either alone or in combination with polymers, to further boost drug solubility and bioavailability. These systems benefit from the surface-active properties of the carriers, which improve wetting, dispersion, and, in some cases, facilitate micelle formation upon dissolution. Commonly employed carriers in this category include Poloxamer 407, Gelucire 44/14, Compritol 888 ATO27, and inulin. These formulations have demonstrated superior dissolution profiles for hydrophobic drugs, making them particularly valuable for enhancing systemic exposure of poorly soluble compounds.

Advantages of solid dispersion technology

Solid dispersion offers several mechanisms for enhancing the solubility and dissolution rate of poorly water-soluble drugs:

- **Reduction in particle size**: Solid dispersion can effectively reduce the drug to a molecular or near-molecular level. Upon dissolution of the carrier matrix, the drug is released as highly dispersed fine particles, resulting in an increased surface area available for dissolution.
- **Enhanced wettability**: The hydrophilic nature of the carrier improves the wetting properties of the drug, thereby promoting faster dissolution in aqueous media.
- **Amorphization of drug**: Drugs in amorphous form lack the ordered crystalline structure, which eliminates the energy barrier associated with lattice disruption during dissolution.
- **Improved uniformity**: Molecular dispersion of the drug ensures better content uniformity and reproducibility in dosage forms.

Overall, solid dispersion represents a robust and versatile platform for improving the bioavailability of hydrophobic drugs and is continuously evolving through advances in carrier systems and processing technologies[6].

Disadvantages of solid dispersions

Despite the promising potential of solid dispersion systems in enhancing the solubility of poorly water-soluble drugs, they are not without limitations. A primary drawback is **physical and chemical instability,** particularly during storage. Over time, solid dispersions may undergo undesirable transformations such as **phase separation, crystallization, or conversion from a metastable to a more stable crystalline form**, resulting in a **decline in dissolution rate and bioavailability**[7,8]. Additionally, exposure to **moisture and temperature fluctuation s**can accelerate these changes, often having a more pronounced deleterious effect compared to simple physical mixtures. Another practical issue encountered during processing is the **tackiness or stickiness** of some formulations, which complicates handling and manufacturing[9].

Limitations of solid dispersion systems

Despite extensive research spanning several decades, the **commercial adoption** of solid dispersion technologies remains relatively limited. Several factors hinder widespread application, including:

1. **Instability of drug or carrier** – both physical and chemical degradation can occur over time.
2. **Challenges in preparation methods** – requiring precise control over process parameters.
3. **Poor reproducibility** – particularly with respect to physicochemical characteristics such as particle size and drug distribution.
4. **Difficulties in formulation** – transforming solid dispersions into suitable dosage forms like tablets or capsules can be complex.
5. **Scale-up issues** – transferring laboratory-scale processes to industrial-scale manufacturing often presents challenges[10].

Types of solid dispersions

Solid dispersions can be categorized based on their **composition or structural arrangement**:

1. Composition-based classification

- **Binary solid dispersions**: Contain a drug and a single polymeric carrier.
- **Ternary solid dispersions**: Include a drug, polymeric carrier, and a surfactant to enhance solubility and stability.

- **Surface solid dispersions**: Involve drug particles adsorbed onto the surface of a hydrophilic polymer such as polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), or PVP-vinyl acetate copolymers, typically prepared using fusion methods to enhance surface wettability and dissolution.

2. Structural and mechanism-based classification

Solid dispersions can also be grouped based on the **arrangement and interaction at the molecular level**, which determines their mechanism of drug release:

- **Type I – simple eutectic mixtures**: Formed by rapid solidification of a molten mixture of drug and carrier. The components crystallize separately and coexist as a finely divided mixture. Example systems include chloramphenicol–urea, paracetamol–urea, and griseofulvin with PEG 2000.
- **Type II – amorphous precipitation in crystalline matrix**: Drug is dispersed in an amorphous state within a crystalline carrier, enhancing dissolution by avoiding crystallization of the drug. For example, sulfathiazole in crystalline urea.
- **Type III – solid solutions**: Both drug and carrier form a homogeneous crystalline or amorphous phase. These are often more effective than eutectic systems because the drug is molecularly dispersed. Solid solutions are further classified as:
  - **Continuous solid solutions**: Drug and carrier are miscible at all ratios in the solid state.
  - **Discontinuous solid solutions**: Miscibility is limited; components crystallize individually.
  - **Substitutional solid solutions**: Drug molecules replace carrier molecules in the lattice.
  - **Interstitial solid solutions**: Drug molecules occupy voids or interstitial sites in the carrier lattice.
  - **Amorphous solid solutions**: Drug is molecularly dispersed in an amorphous carrier without any defined crystal structure.
- **Type IV – Glass suspensions**: Comprise precipitated drug particles dispersed in a glassy carrier matrix.
- **Type V – Glass solutions**: Drug is completely dissolved in the glassy carrier, forming a homogenous single-phase amorphous system. Glassy systems have high solubility potential due to their low lattice energy and absence of crystalline barriers.
- **Type VI – Compound or complex formations**: These involve strong interactions between drug and carrier molecules, potentially forming molecular complexes (e.g., inclusion complexes with

cyclodextrins). These systems depend on a low-to-moderate association constant for effective drug release. When high carrier content is used, a solid solution may also form, enhancing dissolution further[11,12].

Mechanism of drug release from solid dispersions

The mechanism by which drugs are released from solid dispersion systems has been extensively studied and is generally understood to follow two principal pathways: **carrier-controlled release and drug-controlled release.** These mechanisms depend largely on the physicochemical interactions between the drug and the carrier, as well as the dispersion's microstructure.

1. Carrier-controlled release

This mechanism posits that the dissolution rate of the drug is primarily governed by the dissolution characteristics of the polymeric carrier. Corrigan (1986) provided pivotal insights by comparing the dissolution profiles of polyethylene glycol (PEG) as a carrier and drugs incorporated within it. The study demonstrated that the dissolution rate of the drug embedded in PEG closely mirrored that of PEG alone. This led to the hypothesis that the polymer's dissolution behavior regulates drug release.

Further support came from the work of Dubois and Ford (1985), who observed consistent dissolution rates across various drugs formulated with the same carrier under standardized preparation conditions. These findings suggest that, in carrier-controlled systems, the drug becomes molecularly dispersed within a viscous, polymer-rich diffusion layer upon hydration. Because the polymer dissolves rapidly, the drug is released at a rate limited by the carrier, with insufficient time for discrete drug particles to separate out. As a result, the drug remains in a molecularly dispersed state within the hydrated carrier layer during dissolution.

2. Drug-controlled release

In contrast, drug-controlled release is characterized by the drug's intrinsic properties predominantly influencing its dissolution behavior. Sjökvist and Nystrom (1991) provided compelling evidence for this mechanism by measuring the particle size of griseofulvin released from solid dispersions. Their results indicated that smaller particle size of the released drug led to higher dissolution rates, suggesting that particle characteristics play a central role in the release process.

Further clarification was offered by Sjökvist-Sears and Craig (1992), who studied a homologous series of para-aminobenzoates formulated in PEG 6000. They identified a linear correlation between drug solubility and intrinsic dissolution rate within the dispersions. This correlation supports a mechanism

where the **drug's solubility and physical state** rather than the polymer govern the release rate. In such systems, drug particles may not fully molecularly disperse within the polymer matrix. Upon exposure to aqueous media, they are released as fine particulate matter, and the overall dissolution profile is dictated by particle size, crystalline or amorphous form, and surface area. Despite being less dependent on the polymer, drug-controlled dispersions can still demonstrate significantly improved dissolution profiles compared to conventional dosage forms. This is largely due to enhanced **wetting, reduced particle aggregation,** and increased **surface area** of drug particles released from the dispersion matrix[13,14].

Methods used for preparation of solid dispersion

1. Melting (fusion) method

The melting method, also referred to as the fusion technique, involves the formation of a homogeneous mixture by directly heating a physical blend of the active pharmaceutical ingredient (API) and a water-soluble carrier until a molten mass is achieved. This molten mixture is then subjected to rapid cooling—typically via immersion in an ice bath—while being vigorously stirred to promote uniform solidification. The resulting solidified mass is then pulverized, milled, and sieved to obtain the final dispersion. Over time, refinements to this method have been introduced, such as casting the molten mixture onto a ferrite or stainless-steel surface and cooling it with circulating air or water on the reverse side to expedite solidification. A significant advantage of this rapid quenching process is the ability to achieve a supersaturated state, effectively "freezing" drug molecules in an amorphous or finely dispersed crystalline form within the carrier matrix. Despite its benefits, the fusion method has limitations. High processing temperatures can result in thermal degradation or volatilization of heat-sensitive drugs or excipients. To mitigate such degradation, strategies such as heating the mixture in sealed vessels, under vacuum, or in an inert atmosphere (e.g., nitrogen) are employed to minimize oxidation and prevent loss of volatile components[15,16].

2. Solvent evaporation method

The solvent evaporation technique entails dissolving both the drug and the hydrophilic carrier in a shared, volatile organic solvent to create a uniform solution. Upon solvent removal—typically by evaporation under reduced pressure or controlled drying—a solid dispersion is formed. The dried residue is processed further by pulverization and sieving to yield the final product.

This method is particularly advantageous for thermolabile drugs, as it avoids exposure to high temperatures and reduces the risk of thermal degradation. However, the technique presents several challenges:

- **High production cost** due to the use of organic solvents and additional processing steps.
- **Incomplete solvent removal**, which may leave residual solvents that could compromise product safety and regulatory compliance.
- **Chemical instability** of the drug due to trace solvent residues.
- **Requirement for a common volatile solvent** that can dissolve both the drug and carrier efficiently.
- **Polymorphic variability**, as solvent-based crystallization can lead to inconsistent crystal forms.
- **Limited supersaturation**, since achieving a highly supersaturated solid state may be difficult unless the system exhibits significant viscosity.

Despite these limitations, the solvent evaporation method remains a valuable technique, especially when dealing with temperature-sensitive drugs and when precise control over drug dispersion is needed.

3. Melting solvent method (melt evaporation)

The melting solvent method, also known as melt evaporation, involves dissolving the active pharmaceutical ingredient (API) in a suitable organic solvent and incorporating this solution directly into a molten carrier, typically polyethylene glycol (PEG). The mixture is subsequently subjected to solvent evaporation until a clear, solvent-free film remains, which is further dried to a constant weight to obtain the final solid dispersion.PEG 6000 can accommodate up to approximately 5–10% (w/w) of liquid compounds without significant alteration of its solid characteristics. However, miscibility issues may arise between the molten PEG and the solvent or solubilized drug. Additionally, the solvent used may influence the polymorphic form of the drug upon precipitation, potentially affecting dissolution behavior. This method merges the advantages of both the fusion and solvent evaporation techniques, providing improved molecular dispersion and thermal protection. However, due to constraints in solvent handling and drug load, it is best suited for drugs requiring low therapeutic doses (typically <50 mg).

4. Melt extrusion method

The melt extrusion technique involves the continuous processing of a physical mixture of drug and carrier using a twin-screw extruder. During extrusion, the mixture is simultaneously subjected to

melting, homogenization, and shaping, resulting in dosage forms such as tablets, pellets, granules, films, or powders. The extrudates may subsequently be milled and formulated into conventional solid dosage forms.

A major advantage of this method is the short thermal exposure—typically around one minute—which enables the processing of drugs with limited thermal stability. Solid dispersions are typically prepared with drug concentrations up to 40% (w/w). The twin-screw configuration includes multiple mixing and transport zones, allowing for effective blending and uniform dispersion throughout the barrel.

For example, in a representative process, a feed rate of 1 kg/h and a screw speed of 300 rpm are used. The extruder barrel may be divided into five temperature zones maintained at 100°C, 130°C, 170°C, 180°C, and 185°C from the feeding point to the die. After extrusion, the product is cooled on a conveyor belt at room temperature, milled for one minute using a laboratory-scale cutting mill, and sieved to exclude particles larger than 355 μm[17,18].

5. Lyophilization (freeze-drying) technique

Lyophilization, or freeze-drying, is a dehydration process that involves sublimation of ice under low pressure. It serves as an alternative to solvent evaporation and is particularly effective for preparing molecular dispersions of thermolabile drugs. In this technique, both drug and carrier are co-dissolved in a common solvent, frozen, and then dried under vacuum to form a porous, amorphous solid dispersion[19].

6. Melt agglomeration technique

Melt agglomeration is employed to form solid dispersions using a binder that also acts as a carrier. This method may involve either the **melt-in procedure**, where the drug, excipients, and binder are heated above the binder's melting point, or the **spray-on procedure**, wherein a dispersion of drug in molten binder is sprayed onto heated excipients using high-shear mixers. Among these, the rotary processor is often preferred due to better temperature control and its ability to accommodate a higher binder content. Key factors influencing the outcome include the type of binder, manufacturing approach, and particle size of the components. Studies suggest that the melt-in technique often yields higher dissolution rates than the spray-on method when carriers such as PEG 3000, Poloxamer 188, or Glacier 50/13 are used. This is attributed to the uniform immersion and distribution of drug molecules during agglomerate formation. Fine particles promote homogeneous dispersion, whereas larger particles contribute to agglomerate densification[20].

7. Use of surfactant systems

Surfactants play a critical role in enhancing solubilization during solid dispersion preparation. Their adsorption onto solid surfaces can significantly alter properties such as surface energy, hydrophobicity, and surface charge—factors that influence key interfacial phenomena like dispersion, flocculation, wetting, and solubilization. Additionally, surfactants may induce plasticization and reduce the glass transition and melting temperature of drug-carrier systems. This behavior can facilitate the preparation of solid dispersions at lower processing temperatures. These properties have made surfactants highly valuable in enhancing the bioavailability of poorly soluble drugs[21,22].

8. Electrospinning technique

Electrospinning is a fabrication method that creates nanofibers from polymer solutions or melts by applying a high-voltage electric field. In this technique, a polymer solution is extruded through a capillary under an electrostatic field. As the electric field strength reaches a critical point, a **Taylor cone** forms, from which a thin charged polymer jet is emitted[23].

The jet undergoes significant elongation due to Coulombic repulsion forces, and as the solvent evaporates during transit, solid nanofibers are deposited on the collection screen. The simplicity, scalability, and cost-effectiveness of this method make it promising for future applications in controlled drug delivery and preparation of solid dispersions[23].

9. Supercritical fluid (SCF) technology

Supercritical fluid methods, especially those utilizing carbon dioxide (CO_2), have gained attention for solid dispersion and particle size reduction applications. These involve using supercritical CO_2 as an **antisolvent** for the solute but as a **solvent** for the organic phase.

In the **Supercritical Antisolvent (SAS)** process, the drug is dissolved in an organic solvent and introduced into a flowing supercritical CO_2 stream, resulting in rapid precipitation of the drug due to solvent extraction by CO_2. This leads to uniform particle formation and reduced crystal size.SCF processing is typically performed near room temperature, which is beneficial for thermolabile substances. Furthermore, CO_2 can swell or plasticize polymers, reducing the melting temperature of the active ingredient and facilitating melt dispersion at lower energy inputs. Residual CO_2 is minimal and non-toxic, ensuring safe pharmaceutical applications[24].

10. Spray drying technique

Spray drying involves dissolving or dispersing the drug and carrier in a suitable solvent and atomizing the mixture into a drying chamber. The feed is passed through a peristaltic pump to a nozzle at a fixed flow rate. A drying temperature of approximately 120°C (inlet) and 65–70°C (outlet) is maintained, and atomization is controlled by adjusting the spray pressure and airflow rate. Upon rapid solvent evaporation, fine particles are formed and collected using a cyclone separator. This technique allows for rapid processing, uniform particle morphology, and enhanced dissolution characteristics[25].

11. High-pressure homogenization

In this method, the drug is first dispersed in an aqueous surfactant solution and then processed using a high-pressure homogenizer. The mixture is forced through narrow channels at elevated pressure, where intense **cavitation, shear**, and **turbulence** break down drug microparticles into nanoparticles, forming nanosuspensions.

The efficiency of particle size reduction is influenced by drug hardness, applied pressure, and the number of homogenization cycles. This method is particularly suitable for brittle drugs but may not effectively reduce particle size in ductile materials[26].

12. Polymeric alteration

Polymorphism refers to the occurrence of different crystalline forms of the same chemical compound. These polymorphs can differ significantly in terms of melting point, solubility, chemical stability, dissolution rate, and bioavailability. For pharmaceutical development, it is essential to identify and develop the **most thermodynamically stable polymorph** to ensure consistent drug performance over shelf-life and under various storage conditions[27].

13. Inclusion complexation techniques

Inclusion complexes improve drug solubility and stability by encapsulating drug molecules within host structures, such as **cyclodextrins**. The most common methods include:

a) Kneading technique

A small amount of solvent (usually water) is added to a physical mixture of drug and cyclodextrin to form a paste. The paste is kneaded thoroughly, dried at ~45°C, sieved (typically through 30-mesh), and stored in a desiccator.

b) Co-precipitation method

The drug is dissolved in a solution of β-cyclodextrin under constant magnetic stirring and light protection. The resulting precipitate is collected via vacuum filtration and dried at room temperature to maintain the structural integrity of the inclusion complex.

c) Neutralization method

The drug is first solubilized in an alkaline solution such as NaOH or NH_4OH. A solution of β-cyclodextrin is added under agitation to form a complex. Upon neutralization with hydrochloric acid, the inclusion complex precipitates. This precipitate is filtered, washed, and dried.

d) Co-grinding method

Drug and carrier are weighed and mixed with minimal water to form a damp mass, which is sieved (e.g., through a 44-mesh), and dried under vacuum at 60°C until a constant weight is achieved. The product is stored in desiccators until further use.

e) Spray drying method

The drug is dissolved in a volatile solvent, and cyclodextrin is dissolved in water. After forming a homogeneous solution via sonication, the mixture is spray dried to yield inclusion complexes in powder form.

f) Microwave irradiation technique

The drug and cyclodextrin mixture is exposed to microwave radiation to form the inclusion complex. This method is efficient for industrial-scale production due to shorter processing time and higher product yields[28,29].

Practical limitations in solid dispersion techniques

Solid dispersion technologies offer significant advantages for enhancing the solubility and bioavailability of poorly water-soluble drugs. However, practical challenges arise during formulation development, scale-up, and long-term stability of the final product. These limitations and corresponding mitigation strategies are discussed below.

1. Challenges in dosage form development

a. Poor flowability and compressibility

Solid dispersions often exhibit poor flow properties and limited compressibility due to their amorphous or semi-crystalline nature, making them difficult to handle during downstream processing

such as sieving, blending, or tableting. Additionally, stability issues may arise, particularly during pulverization and storage.

To address this, ***in-situ* granulation** techniques have been developed. In this approach, excipients like calcium hydrogen phosphate and sodium starch glycolate are pre-heated and mixed in a water-jacketed blender at approximately 70°C. Subsequently, a molten drug-carrier mixture (heated to 100°C) is introduced into the rotating powder bed. After thorough mixing, the semi-solid mass is passed through a 20-mesh sieve and hardened at room temperature (25°C) for 12 hours. The resulting granules are then blended with a higher concentration of lubricant (e.g., 1% magnesium stearate) and compressed into tablets. It is worth noting that conventional wet granulation is not suitable for these systems due to potential disruption of the solid dispersion matrix upon water exposure.

b. Adhesion of granules to punches and dies

During compression, solid dispersion granules may adhere to metallic surfaces of punches and dies, resulting in inconsistent tablet quality and operational inefficiencies. One preventive measure involves placing a thin layer of greaseproof paper between the granules and metal surfaces to minimize direct contact.

Alternatively, solid dispersions, especially drug-polyethylene glycol (PEG) melts, can be encapsulated directly into **hard gelatin capsules**. Care must be taken to ensure that the fill temperature does not exceed 70°C to avoid compromising the structural integrity of the capsules[30,31].

2. Challenges in scale-up and manufacturing

a. Moisture condensation during cooling

In scaled-up processes, the risk of **moisture condensation** during the cooling of molten dispersions is significant, which may adversely affect the stability and integrity of the formulation. To mitigate this, **continuous cooling techniques**—such as cooling on moving or rotating belts—are employed. These approaches ensure uniform cooling and minimize moisture uptake from the environment.

b. Variability in physicochemical properties

The **physicochemical characteristics** of solid dispersions prepared via hot-melt methods are highly sensitive to process variables. Parameters such as heating rate, peak processing temperature, dwell time at elevated temperature, cooling method and rate, pulverization technique, and resulting particle size significantly impact the final product.

Variations in these parameters can lead to inconsistencies in **crystallinity, particle morphology, and dissolution behavior**, as evidenced by changes in powder X-ray diffraction patterns. Therefore, stringent control of manufacturing conditions is essential to ensure product reproducibility[32].

3. Challenges in stability

Solid dispersions generated via melt extrusion or hot melt techniques often contain **molecularly dispersed drug fractions** within the carrier matrix. Over time, these systems are susceptible to **phase separation**, leading to the formation of crystalline and amorphous regions, which compromises drug stability and performance. To combat this, **polymeric stabilizers** such as **polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), and HPMCAS (HPMC acetate succinate)** are commonly incorporated. These polymers inhibit crystallization by increasing the **kinetic barrier to nucleation** and thereby maintaining the amorphous state of the drug. The efficiency of this stabilizing effect is typically **concentration-dependent** but largely independent of the polymer's intrinsic physicochemical properties[33].

Newer technological approaches

1. **Use of surface-active agents**

A notable advancement in solid dispersion technology is the incorporation of **surface-active carriers** to enhance drug dissolution. When drug-PEG melts are encapsulated into hard gelatin capsules, a **drug-rich layer** may form at the dissolution interface, especially for drugs with poor aqueous solubility. This layer hinders further dissolution and results in incomplete drug release.

To overcome this, **surface-active agents** such as **Gelucire 44/14**and**Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate)** are used as carriers. These agents act as **wetting and emulsifying agents,** facilitating uniform dispersion of the drug upon hydration and preventing the formation of water-insoluble surface films. The resulting formulations exhibit **enhanced wettability, improved dissolution profiles,** and more consistent bioavailability.

2. **Use of block co-polymers as dispersing agents**

The application of surface-active agents in solid dispersion formulations has shown considerable potential in enhancing the solubility and dissolution rate of poorly water-soluble drugs. However, the use of certain conventional surfactants may be associated with **toxicity concerns**, especially at higher concentrations. This has prompted the exploration of safer and more effective alternatives. One such promising class of solubilizing agents is **blocking co-polymers**, particularly those composed of **polyethylene oxide (PEO)**and **polypropylene oxide (PPO)** segments. These amphiphilic

macromolecules self-assemble in aqueous environments to form **monomolecular micelles** at critical concentrations. With increasing concentration, these micelles can further aggregate into **larger supramolecular structures**, characterized by a **hydrophobic core shielded by hydrophilic outer layers.**

This unique architecture allows block co-polymers to encapsulate and **solubilize hydrophobic drug molecules**within their core, thereby significantly enhancing the drug's apparent solubility and dissolution rate. Additionally, these polymers provide a stabilizing microenvironment, which helps **maintain the drug in its solubilized state** and reduces the risk of precipitation or recrystallization during storage or upon administration.

Moreover, block co-polymers can contribute to the **physical and chemical stability** of the solid dispersion system. By stabilizing the amorphous or molecularly dispersed state of the drug, they help to prevent **phase separation,** crystallization, or degradation, thus extending the product's shelf life.

3. **Examples of block co-polymers in solid dispersion**

- **Pluronics (Poloxamers):** Triblock copolymers consisting of a central hydrophobic PPO block flanked by hydrophilic PEO blocks, e.g., **Poloxamer 188**, **Poloxamer 407**.
- **Poly(β-benzyl-L-aspartate)-block-poly (ethylene oxide):** A biodegradable and biocompatible block co-polymer used in drug delivery systems.
- **PEG-PPO-PEG systems:** Known for their ability to enhance solubility and provide thermodynamic stability to the formulation.

In conclusion, **block co-polymers** not only serve as effective **solubilizing agents** but also contribute significantly to the **stability** of solid dispersion formulations, offering a biocompatible and safe alternative to traditional surfactants.

Applications of Solid Dispersions

Solid dispersion technology offers several significant advantages in pharmaceutical formulation, particularly for poorly water-soluble drugs. Key applications include:

1. **Enhancement of solubility and bioavailability:** Solid dispersions are widely used to improve the aqueous solubility of poorly soluble drug molecules, thereby increasing their dissolution rate, absorption, and ultimately, bioavailability.

2. **Stabilization of labile drug molecules:** This approach helps protect chemically unstable drugs from degradation pathways such as hydrolysis, oxidation, photodegradation, isomerization, and recrystallization.
3. **Reduction of adverse effects:** By modifying drug release characteristics and targeting delivery, solid dispersions can help minimize local irritation and systemic side effects of certain drugs.
4. **Taste and odour masking:** The encapsulation of drugs in carriers can effectively mask unpleasant organoleptic properties, improving patient compliance.
5. **Enhanced topical delivery:** Solid dispersion systems can improve the release profile of active pharmaceutical ingredients from semisolid formulations such as creams, ointments, and gels.
6. **Avoidance of drug–excipient incompatibilities:** Molecular dispersion of drugs may prevent undesired physicochemical interactions in multi-component formulations.
7. **Uniform drug distribution:** This technique enables the homogeneous dispersion of small quantities of drug throughout the solid matrix, which is especially beneficial in low-dose formulations.
8. **Solidification of liquid or volatile compounds:** Solid dispersions can be used to incorporate liquid (up to ~10%) or gaseous drugs into a solid dosage form for improved stability and handling.
9. **Combination dosage forms:** Solid dispersions enable the formulation of a rapid-release loading dose combined with a sustained-release component in a single dosage unit.
10. **Sustained release of soluble drugs:** By employing poorly soluble or insoluble carriers, the release of highly soluble drugs can be modulated to achieve sustained-release profiles.
11. **Reduction of first-pass metabolism:** Certain solid dispersion strategies can reduce the pre-systemic metabolism of drugs such as morphine and progesterone, enhancing their systemic availability[34-36].

CONCLUSION

The limited aqueous solubility of many newly developed drug candidates remains a significant hurdle in achieving optimal oral bioavailability. Since dissolution rate is often the rate-limiting step in absorption, improving solubility is a critical focus in formulation science. Among the various solubility enhancement techniques, solid dispersion has emerged as a robust and versatile approach. Solid dispersions have been successfully employed over the past few decades to enhance the solubility

and dissolution characteristics of poorly soluble drugs. However, widespread commercial application is still limited due to practical challenges including scalability, cost-efficiency, and the physical or chemical instability of certain drug-carrier systems. To fully exploit the potential of solid dispersion technology, ongoing research and technological advancements are required—particularly in process optimization, material selection, and stabilization strategies. When these challenges are addressed, solid dispersions hold great promise as a reliable and industrially viable solution for enhancing the performance of poorly soluble drug compounds.

REFERENCES

1. Wadke DA, Serajuddin A and Jacobson H, "Preformulation testing". In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical Dosage Forms: Tablets. New York, NY: Marcel Dekker; 1989.
2. Brahmankar DM and Jaiswal SB. Biopharmaceutics and Pharmacokinetics, Vallabh Prakashan, 1st Edn. 1995:347-352
3. Patel PB, Prajapati ST, Patel NR, Patel NN and Patel CN. Solid Dispersion: A Method of Improving Bioavailability and Taste Masking. Inventi Rapid: Pharm Tech Vol. 2012; Issue 4.
4. Patidar K, Sharma S, Soni M, Kshirsagar MD and Saini V. Preparation and Characterization of Hydrotrophic Solid Dispersions of Indomethacin. Inventi Rapid: Pharm Tech. Vol. 1, Issue 3
5. Wairkar SM and Gaud RS. Solid Dispersions: Solubility enhancement technique for poorly soluble drugs. International Journal of Research in Pharmaceutical and Biomedical Sciences. 2013; 4 (3):847-854.
6. Remington- The Science & Practice of Pharmacy, Published by Lippincott Williams & Wilkins. 21st Edn., 229-230
7. X. Wang, Michel A, and Van den MG. Solid state characteristics of ternary solid Dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int. J. Pharm,2005;303(1):54-61.
8. Seth NS. Formulation and evaluation of solid dispersion of olanzepine, Int. J. Pharm. Sci. Res. 2011;2(2):691-697.
9. Chavan S, Patel K, Shelar D and Vavia P. Preparation of Oxcarbazine Solid Dispersion by Hot Melt Extrusion for Enhanced Dissolution: Doenstream Processing to tablets. Am. J. PharmTech Res. 2013;3 (1).
10. Ingle US, Gaikwad PD, Bankar VH, et al. A Review on solid dispersion: A dissolution enhancement technique. International Journal of Research in Ayurveda & Pharmacy. 2011;2 (3):751-757.

11. Duncan QM Craig. The Mechanism of Drug release from Solid Dispersions and Water soluble polymers. International Journal of Pharmaceutics. 2002; 231:131- 144.
12. Leuner C and Dressman J. Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics. 2000;50: 47- 60.
13. Nagender Reddy CH, Anil Reddy T and Srinivasan S. Review on: Better solubility enhancement of poorly water-soluble drugs. International Journal of Inventions in Pharmaceutical Sciences. 2013;1(4):267- 273.
14. Eun-Jung Kim, *et al*. Preparation of solid dispersion of felodipine using a solvent wetting method. European Journal of Pharmaceutics and Biopharmaceutics. 2006;64:200-205,
15. Bhujbal SV, Mitra B, Jain U, Gong Y, Agrawal A, Karki S, Taylor LS, Kumar S and Zhou QT. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharmaceutica Sinica B. 2021;11(8):2505-36.
16. Mir KB and Khan NA. Solid dispersion: Overview of the technology. Int J Pharm Sci Res. 2017;8(6):2378-87.
17. Vasconcelos T, Marques S, das Neves J and Sarmento B. Amorphous solid dispersions: Rational selection of a manufacturing process. Advanced drug delivery reviews. 2016; 100:85-101.
18. Tran P, Pyo YC, Kim DH, Lee SE, Kim JK and Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics. 2019;11(3):132.
19. Malkawi R, Malkawi WI, Al-Mahmoud Y and Tawalbeh J. Current trends on solid dispersions: past, present, and future. Advances in Pharmacological and Pharmaceutical Sciences. 2022;2022(1):5916013.
20. Singh A and Van den Mooter G. Spray drying formulation of amorphous solid dispersions. Advanced drug delivery reviews. 2016; 100:27-50.
21. Singh D, Bedi N and Tiwary AK. Enhancing solubility of poorly aqueous soluble drugs: Critical appraisal of techniques. Journal of pharmaceutical investigation. 2018; 48:509-26.
22. Jermain SV, Brough C and Williams III RO. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery–an update. International journal of pharmaceutics. 2018; 535(1-2):379-92.
23. Cid AG, Simonazzi A, Palma SD and Bermúdez JM. Solid dispersion technology as a strategy to improve the bioavailability of poorly soluble drugs. Therapeutic delivery. 2019;10(6):363-82.
24. Chavan RB, Rathi S, Jyothi VG and Shastri NR. Cellulose based polymers in development of amorphous solid dispersions. Asian journal of pharmaceutical sciences. 2019;14(3):248-64.

25. Li N and Taylor LS. Tailoring supersaturation from amorphous solid dispersions. Journal of Controlled Release. 2018; 279:114-25.
26. Hallouard F, Mehenni L, Lahiani-Skiba M, Anouar Y and Skiba M. Solid dispersions for oral administration: An overview of the methods for their preparation. Current pharmaceutical design. 2016;22(32):4942-58.
27. Chaudhari SP and Dugar RP. Application of surfactants in solid dispersion technology for improving solubility of poorly water-soluble drugs. Journal of drug delivery science and technology. 2017; 41:68-77.
28. Zhang X, Xing H, Zhao Y and Ma Z. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics. 2018;10(3):74.
29. Dhande LB, Deshmukh MT, Khopade AN, Shete RV andKunjir VV. A review on solubility enhancement by solid dispersion method. Journal of Drug Delivery and Therapeutics. 2021;11(1):182-7.
30. Attia MS, Hasan AA, Ghazy FE and Gomaa E. Solid dispersion as a technical solution to boost the dissolution rate and bioavailability of poorly water-soluble drugs. Indian Journal of Pharmaceutical Education and Research. 2021;55(2s): s327-39.
31. Kumar S and Singh P. Various techniques for solubility enhancement: An overview. The Pharma Innovation. 2016; 5(1, A):23.
32. Tayyab Ansari M, Arshad MS, Hussain A and Ahmad Z. Improvement of solubility, dissolution and stability profile of artemether solid dispersions and self-emulsified solid dispersions by solvent evaporation method. Pharmaceutical development and technology. 2018;23(10):1007-15.
33. Hughey JR, Huang S and Williams III RO. Solid-state techniques for improving solubility. In Formulating poorly water-soluble drugs 2016 Dec 17 (pp. 121-163). Cham: Springer International Publishing.
34. Wani SU, Kakkar V, Gautam SP, Gangadhar Appa HV, Ali M, Masoodi MH and Moin A. Enhancing therapeutic potential of poor aqueous soluble herbal drugs through solid dispersion-An overview. Phytomedicine Plus. 2021;1(4):100069.
35. Tripathy D, Nayak BS, Mohanty B and Mishra B. Solid dispersion: A technology for improving aqueous solubility of drug. J. Pharm. Adv. Res. 2019;2(7):577-86.
36. Bhalani DV, Nutan B, Kumar A and Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines. 2022;10(9):2055.